On 23 February, Boston Scientific announced the first implants of a Teligen implantable cardioverter defibrillator (ICD) in China. The implants were performed by Farong Shen, Zhejiang Hospital, Hangzhou, and Wei Hua, Fuwai Hospital, Beijing.
According to a company release, the Teligen family of ICDs, designed to treat sudden cardiac death, are the smallest and thinnest high-energy devices available in China. The devices offer extended battery longevity over previous Boston Scientific ICDs currently approved in China, as well as improved programming technology to offer patients enhanced clinical options.
Shu Zhang, chairman of the Chinese Society of Pacing and Electrophysiology, said: “These new ICDs feature significant advances and will be a welcome technology for Chinese patients requiring implantable defibrillators.”
“The Teligen devices provide patients the thinnest ICDs with the longest projected longevity available, without compromising therapy options,” Hua said.
“In the past, I often had to sacrifice longevity, device size, or features when selecting an ICD for my patients. The Teligen device delivers a complete solution,” Shen also added.
The Teligen family of devices was approved by the State Food and Drug Administration (SFDA) of the People’s Republic of China in November 2011.